Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
- PMID: 11351307
- DOI: 10.1002/ijc.1282
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
Erratum in
- Int J Cancer 2002 Feb 20;97(6):878
Abstract
NY-ESO-1, a member of the CT (cancer/testis) family of antigens, is expressed in normal testis and in a range of human tumor types. Knowledge of NY-ESO-1 expression has depended on RT-PCR detection of mRNA and there is a need for detecting NY-ESO-1 at the protein level. In the present study, a method for the immunochemical detection of NY-ESO-1 in paraffin-embedded tissues has been developed and used to define the expression pattern of NY-ESO-1 in normal tissues and in a panel of human tumors. No normal tissue other than testis showed NY-ESO-1 reactivity, and expression in testis was restricted to germ cells particularly spermatogonia. In human tumors, the frequency of NY-ESO-1 antigen expression corresponds with past analysis of NY-ESO-1 mRNA expression e.g., 20-30% of lung cancers, bladder cancers and melanoma, and no expression in colon and renal cancer. Co-typing of NY-ESO-1 antigen and mRNA expression in a large panel of lung cancers showed a good correlation. There is great variability in NY-ESO-1 expression in individual tumors, ranging from an infrequent homogeneous pattern of staining to highly heterogeneous antigen expression.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.Clin Cancer Res. 2004 Dec 15;10(24):8396-404. doi: 10.1158/1078-0432.CCR-04-0809. Clin Cancer Res. 2004. PMID: 15623618
-
Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number.Int J Oncol. 2005 Jan;26(1):57-63. Int J Oncol. 2005. PMID: 15586225
-
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.Cancer Immun. 2003 Dec 18;3:19. Cancer Immun. 2003. PMID: 14680360
-
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.J Transl Med. 2020 Mar 27;18(1):140. doi: 10.1186/s12967-020-02306-y. J Transl Med. 2020. PMID: 32220256 Free PMC article. Review.
-
NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.Chin Clin Oncol. 2018 Aug;7(4):44. doi: 10.21037/cco.2018.08.11. Chin Clin Oncol. 2018. PMID: 30173534 Review.
Cited by
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.Oncoimmunology. 2021 Mar 26;10(1):1898105. doi: 10.1080/2162402X.2021.1898105. Oncoimmunology. 2021. PMID: 33796406 Free PMC article. Clinical Trial.
-
Cancer-testis antigen expression and immunogenicity in AL amyloidosis.Blood Cancer J. 2012 Sep 14;2(9):e90. doi: 10.1038/bcj.2012.32. Blood Cancer J. 2012. PMID: 22983433 Free PMC article.
-
Rational design of innate defense regulator peptides as tumor vaccine adjuvants.NPJ Vaccines. 2021 May 20;6(1):75. doi: 10.1038/s41541-021-00334-3. NPJ Vaccines. 2021. PMID: 34016984 Free PMC article.
-
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma.Cancer Immunol Immunother. 2005 Apr;54(4):400-6. doi: 10.1007/s00262-004-0603-z. Epub 2004 Sep 24. Cancer Immunol Immunother. 2005. PMID: 15449039 Free PMC article.
-
A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.J Transl Med. 2005 Jul 26;3:29. doi: 10.1186/1479-5876-3-29. J Transl Med. 2005. PMID: 16045799 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous